1
|
Seneviratne DS, Saifi O, Mackeyev Y, Malouff T, Krishnan S. Next-Generation Boron Drugs and Rational Translational Studies Driving the Revival of BNCT. Cells 2023; 12:1398. [PMID: 37408232 DOI: 10.3390/cells12101398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 04/26/2023] [Accepted: 05/04/2023] [Indexed: 07/07/2023] Open
Abstract
BNCT is a high-linear-energy transfer therapy that facilitates tumor-directed radiation delivery while largely sparing adjacent normal tissues through the biological targeting of boron compounds to tumor cells. Tumor-specific accumulation of boron with limited accretion in normal cells is the crux of successful BNCT delivery. Given this, developing novel boronated compounds with high selectivity, ease of delivery, and large boron payloads remains an area of active investigation. Furthermore, there is growing interest in exploring the immunogenic potential of BNCT. In this review, we discuss the basic radiobiological and physical aspects of BNCT, traditional and next-generation boron compounds, as well as translational studies exploring the clinical applicability of BNCT. Additionally, we delve into the immunomodulatory potential of BNCT in the era of novel boron agents and examine innovative avenues for exploiting the immunogenicity of BNCT to improve outcomes in difficult-to-treat malignancies.
Collapse
Affiliation(s)
| | - Omran Saifi
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA
| | - Yuri Mackeyev
- Department of Neurosurgery, UTHealth, Houston, TX 77030, USA
| | - Timothy Malouff
- Department of Radiation Oncology, University of Oklahoma, Oklahoma City, OK 73019, USA
| | - Sunil Krishnan
- Department of Neurosurgery, UTHealth, Houston, TX 77030, USA
| |
Collapse
|
2
|
Olaiz N, Monti Hughes A, Pozzi ECC, Thorp S, Curotto P, Trivillin VA, Ramos PS, Palmieri MA, Marshall G, Schwint AE, Garabalino MA. Enhancement in the Therapeutic Efficacy of In Vivo BNCT Mediated by GB-10 with Electroporation in a Model of Oral Cancer. Cells 2023; 12:cells12091241. [PMID: 37174642 PMCID: PMC10177359 DOI: 10.3390/cells12091241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/17/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) combines preferential tumor uptake of 10B compounds and neutron irradiation. Electroporation induces an increase in the permeability of the cell membrane. We previously demonstrated the optimization of boron biodistribution and microdistribution employing electroporation (EP) and decahydrodecaborate (GB-10) as the boron carrier in a hamster cheek pouch oral cancer model. The aim of the present study was to evaluate if EP could improve tumor control without enhancing the radiotoxicity of BNCT in vivo mediated by GB-10 with EP 10 min after GB-10 administration. Following cancerization, tumor-bearing hamster cheek pouches were treated with GB-10/BNCT or GB-10/BNCT + EP. Irradiations were carried out at the RA-3 Reactor. The tumor response and degree of mucositis in precancerous tissue surrounding tumors were evaluated for one month post-BNCT. The overall tumor response (partial remission (PR) + complete remission (CR)) increased significantly for protocol GB-10/BNCT + EP (92%) vs. GB-10/BNCT (48%). A statistically significant increase in the CR was observed for protocol GB-10/BNCT + EP (46%) vs. GB-10/BNCT (6%). For both protocols, the radiotoxicity (mucositis) was reversible and slight/moderate. Based on these results, we concluded that electroporation improved the therapeutic efficacy of GB-10/BNCT in vivo in the hamster cheek pouch oral cancer model without increasing the radiotoxicity.
Collapse
Affiliation(s)
- Nahuel Olaiz
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Andrea Monti Hughes
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Silvia Thorp
- Sub-Gerencia Instrumentación y Control, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Ezeiza (CAE), Camino Real Presbítero González y Aragón 15, Buenos Aires B1802AYA, Argentina
| | - Verónica A Trivillin
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Paula S Ramos
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Mónica A Palmieri
- Departamento de Biodiversidad y Biología Experimental, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón II, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
| | - Guillermo Marshall
- Departamento de Física, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires (UBA), Pabellón I, Ciudad Universitaria, Buenos Aires C1428EHA, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
| | - Amanda E Schwint
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2270, Buenos Aires C1425FQD, Argentina
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| | - Marcela A Garabalino
- Departamento Radiobiología, Comisión Nacional de Energía Atómica (CNEA), Centro Atómico Constituyentes (CAC), Av. General Paz 1499, San Martín, Buenos Aires B1650KNA, Argentina
| |
Collapse
|
3
|
Garabalino MA, Olaiz N, Portu A, Saint Martin G, Thorp SI, Pozzi ECC, Curotto P, Itoiz ME, Monti Hughes A, Colombo LL, Nigg DW, Trivillin VA, Marshall G, Schwint AE. Electroporation optimizes the uptake of boron-10 by tumor for boron neutron capture therapy (BNCT) mediated by GB-10: a boron biodistribution study in the hamster cheek pouch oral cancer model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2019; 58:455-467. [PMID: 31123853 DOI: 10.1007/s00411-019-00796-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Accepted: 05/07/2019] [Indexed: 05/17/2023]
Abstract
Boron neutron capture therapy (BNCT) is a promising cancer binary therapy modality that utilizes the nuclear capture reaction of thermal neutrons by boron-10 resulting in a localized release of high- and low-linear energy transfer (LET) radiation. Electrochemotherapy (ECT) is based on electroporation (EP) that induces opening of pores in cell membranes, allowing the entry of compounds. Because EP is applied locally to a tumor, the compound is incorporated preferentially by tumor cells. Based on the knowledge that the therapeutic success of BNCT depends centrally on the boron content in tumor and normal tissues and that EP has proven to be an excellent facilitator of tumor biodistribution of an anti-tumor agent, the aim of this study was to evaluate if EP can optimize the delivery of boronated compounds. We performed biodistribution studies and qualitative microdistribution analyses of boron employing the boron compound sodium decahydrodecaborate (GB-10) + EP in the hamster cheek pouch oral cancer model. Syrian hamsters with chemically induced exophytic squamous cell carcinomas were used. A typical EP treatment was applied to each tumor, varying the moment of application with respect to the administration of GB-10 (early or late). The results of this study showed a significant increase in the absolute and relative tumor boron concentration and optimization of the qualitative microdistribution of boron by the use of early EP + GB-10 versus GB-10 without EP. This strategy could be a tool to improve the therapeutic efficacy of BNCT/GB-10 in vivo.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina.
| | - Nahuel Olaiz
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Agustina Portu
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Gisela Saint Martin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Silvia I Thorp
- Sub-gerencia Instrumentación y Control, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
| | - Emiliano C C Pozzi
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Paula Curotto
- Departamento de Reactores de Investigación y Producción, Centro Atómico Ezeiza, Camino Real Presbítero González y Aragón 15, B1802AYA, Ezeiza, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - María E Itoiz
- Departamento de Anatomía Patología, Facultad de Odontología, Universidad de Buenos Aires, Marcelo T. de Alvear 2142, C1122AAH, Ciudad Autónoma De Buenos Aires, Argentina
| | - Andrea Monti Hughes
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Lucas L Colombo
- Instituto de Oncología Angel H. Roffo, Avenida San Martin 5481, C1417DTB, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - David W Nigg
- Idaho National Laboratory, 2525 Fremont Ave, Idaho Falls, ID, 83402, USA
| | - Verónica A Trivillin
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Guillermo Marshall
- Departamento de Sistemas complejos, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pabellón II, C1428EHA, Ciudad Autónoma De Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| | - Amanda E Schwint
- Departamento de Radiobiología, Comisión Nacional de Energía Atómica, Centro Atómico Constituyentes, Avenida General Paz 1499, B1650KNA, San Martin, Provincia Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Godoy Cruz 2290, C1425FQB, Cuidad Autónoma De Buenos Aires, Argentina
| |
Collapse
|
4
|
Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond) 2018; 38:35. [PMID: 29914561 PMCID: PMC6006782 DOI: 10.1186/s40880-018-0299-7] [Citation(s) in RCA: 220] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 05/08/2018] [Indexed: 02/07/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary radiotherapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope, boron-10, is irradiated with neutrons to produce high energy alpha particles. This review will focus on tumor-targeting boron delivery agents that are an essential component of this binary system. Two low molecular weight boron-containing drugs currently are being used clinically, boronophenylalanine (BPA) and sodium borocaptate (BSH). Although they are far from being ideal, their therapeutic efficacy has been demonstrated in patients with high grade gliomas, recurrent tumors of the head and neck region, and a much smaller number with cutaneous and extra-cutaneous melanomas. Because of their limitations, great effort has been expended over the past 40 years to develop new boron delivery agents that have more favorable biodistribution and uptake for clinical use. These include boron-containing porphyrins, amino acids, polyamines, nucleosides, peptides, monoclonal antibodies, liposomes, nanoparticles of various types, boron cluster compounds and co-polymers. Currently, however, none of these have reached the stage where there is enough convincing data to warrant clinical biodistribution studies. Therefore, at present the best way to further improve the clinical efficacy of BNCT would be to optimize the dosing paradigms and delivery of BPA and BSH, either alone or in combination, with the hope that future research will identify new and better boron delivery agents for clinical use.
Collapse
Affiliation(s)
- Rolf F. Barth
- Department of Pathology, The Ohio State University, 4132 Graves Hall, 333 W. 10th Ave, Columbus, OH 43210 USA
| | - Peng Mi
- Department of Radiology, Center for Medical Imaging, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan 610041 P. R. China
| | - Weilian Yang
- Department of Pathology, The Ohio State University, 4132 Graves Hall, 333 W. 10th Ave, Columbus, OH 43210 USA
- Present Address: Neurosurgery and Brain and Nerve Research Laboratory, The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu 215004 P. R. China
| |
Collapse
|
5
|
Portu A, Molinari AJ, Thorp SI, Pozzi ECC, Curotto P, Schwint AE, Saint Martin G. Neutron autoradiography to study boron compound microdistribution in an oral cancer model. Int J Radiat Biol 2015; 91:329-35. [PMID: 25510259 DOI: 10.3109/09553002.2014.995381] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE We previously reported the therapeutic efficacy of Sequential Boron Neutron Capture Therapy (Seq-BNCT), i.e., BPA (boronophenylalanine) - BNCT followed by GB-10 (decahydrodecaborate) - BNCT 1 or 2 days later, in the hamster cheek pouch oral cancer model. We have utilized the neutron autoradiography methodology to study boron microdistribution in tissue. The aim was to use this method to evaluate if the distribution of GB-10 is altered by prior application of BPA-BNCT in Sequential BNCT protocols. MATERIALS AND METHODS Extensive qualitative and quantitative autoradiography analyses were performed in the following groups: G1 (animals without boron); G2 (animals injected with BPA); G3 (animals injected with GB-10); G4 (same as G3, 24 h after BPA-BNCT); and G5 (same protocol as G4, 48 h interval). RESULTS A detailed study of boron localization in the different tissue structures of tumor, premalignant and normal tissue in the hamster cheek pouch was performed. GB-10 accumulated preferentially in non-neoplastic connective tissue, whereas for BPA neoplastic cells showed the highest boron concentration. Boron distribution was less heterogeneous for GB-10 than for BPA. In premalignant and normal tissue, GB-10 and BPA accumulated mostly in connective tissue and epithelium, respectively. CONCLUSIONS BPA-BNCT could alter boron microlocalization of GB-10 administered subsequently. Boron targeting homogeneity is essential for therapeutic success.
Collapse
Affiliation(s)
- Agustina Portu
- National Atomic Energy Commission (CNEA) , San Martin, Buenos Aires , Argentina
| | | | | | | | | | | | | |
Collapse
|
6
|
Monti-Hughes A, Aromando RF, Pérez MA, Schwint AE, Itoiz ME. The hamster cheek pouch model for field cancerization studies. Periodontol 2000 2014; 67:292-311. [DOI: 10.1111/prd.12066] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/2014] [Indexed: 12/13/2022]
|
7
|
Trivillin VA, Abramson DB, Bumaguin GE, Bruno LJ, Garabalino MA, Monti Hughes A, Heber EM, Feldman S, Schwint AE. Boron neutron capture synovectomy (BNCS) as a potential therapy for rheumatoid arthritis: boron biodistribution study in a model of antigen-induced arthritis in rabbits. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2014; 53:635-643. [PMID: 25156017 DOI: 10.1007/s00411-014-0564-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 08/14/2014] [Indexed: 06/03/2023]
Abstract
Boron neutron capture synovectomy (BNCS) is explored for the treatment of rheumatoid arthritis (RA). The aim of the present study was to perform boron biodistribution studies in a model of antigen-induced arthritis (AIA) in female New Zealand rabbits, with the boron carriers boronophenylalanine (BPA) and sodium decahydrodecaborate (GB-10) to assess the potential feasibility of BNCS for RA. Rabbits in chronic phase of AIA were used for biodistribution studies employing the following protocols: intra-articular (ia) (a) BPA-f 0.14 M (0.7 mg (10)B), (b) GB-10 (5 mg (10)B), (c) GB-10 (50 mg (10)B) and intravenous (iv), (d) BPA-f 0.14 M (15.5 mg (10)B/kg), (e) GB-10 (50 mg (10)B/kg), and (f) BPA-f (15.5 mg (10)B/kg) + GB-10 (50 mg (10)B/kg). At different post-administration times (13-85 min for ia and 3 h for iv), samples of blood, pathological synovium (target tissue), cartilage, tendon, muscle, and skin were taken for boron measurement by inductively coupled plasma mass spectrometry. The intra-articular administration protocols at <40 min post-administration both for BPA-f and GB-10, and intravenous administration protocols for GB-10 and [GB-10 + BPA-f] exhibited therapeutically useful boron concentrations (>20 ppm) in the pathological synovium. Dosimetric estimations suggest that BNCS would be able to achieve a therapeutically useful dose in pathological synovium without exceeding the radiotolerance of normal tissues in the treatment volume, employing boron carriers approved for use in humans. Radiobiological in vivo studies will be necessary to determine the actual therapeutic efficacy of BNCS to treat RA in an experimental model.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Comisión Nacional de Energía Atómica (CNEA), Avenida General Paz 1499, B1650KNA, San Martin, Provincia de Buenos Aires, Argentina,
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Garabalino MA, Heber EM, Monti Hughes A, Pozzi ECC, Molinari AJ, Nigg DW, Bauer W, Trivillin VA, Schwint AE. Boron biodistribution for BNCT in the hamster cheek pouch oral cancer model: combined administration of BSH and BPA. Appl Radiat Isot 2013; 88:64-8. [PMID: 24360859 DOI: 10.1016/j.apradiso.2013.11.118] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 11/27/2013] [Accepted: 11/28/2013] [Indexed: 11/18/2022]
Abstract
Sodium mercaptoundecahydro-closo-dodecaborate (BSH) is being investigated clinically for BNCT. We examined the biodistribution of BSH and BPA administered jointly in different proportions in the hamster cheek pouch oral cancer model. The 3 assayed protocols were non-toxic, and showed preferential tumor boron uptake versus precancerous and normal tissue and therapeutic tumor boron concentration values (70-85ppm). All 3 protocols warrant assessment in BNCT studies to contribute to the knowledge of (BSH+BPA)-BNCT radiobiology for head and neck cancer and optimize therapeutic efficacy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Verónica A Trivillin
- National Atomic Energy Commission (CNEA), Argentina; National Research Council (CONICET), Argentina
| | - Amanda E Schwint
- National Atomic Energy Commission (CNEA), Argentina; National Research Council (CONICET), Argentina.
| |
Collapse
|
9
|
Garabalino MA, Heber EM, Monti Hughes A, González SJ, Molinari AJ, Pozzi ECC, Nievas S, Itoiz ME, Aromando RF, Nigg DW, Bauer W, Trivillin VA, Schwint AE. Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2013; 52:351-361. [PMID: 23591915 DOI: 10.1007/s00411-013-0467-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 03/23/2013] [Indexed: 06/02/2023]
Abstract
Boron neutron capture therapy (BNCT) is based on selective accumulation of ¹⁰B carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg ¹⁰B/kg) was administered to tumor-bearing hamsters. Groups of 3-5 animals were killed humanely at nine time-points, 3-12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24-35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7-11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Department of Radiobiology, National Atomic Energy Commission-CNEA, Avenida General Paz 1499, B1650KNA, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Heber EM, Kueffer PJ, Lee MW, Hawthorne MF, Garabalino MA, Molinari AJ, Nigg DW, Bauer W, Hughes AM, Pozzi ECC, Trivillin VA, Schwint AE. Boron delivery with liposomes for boron neutron capture therapy (BNCT): biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2012; 51:195-204. [PMID: 22271404 DOI: 10.1007/s00411-011-0399-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2011] [Accepted: 12/27/2011] [Indexed: 05/31/2023]
Abstract
Boron neutron capture therapy (BNCT) combines selective accumulation of (10)B carriers in tumor tissue with subsequent neutron irradiation. We previously demonstrated the therapeutic efficacy of BNCT in the hamster cheek pouch oral cancer model. Optimization of BNCT depends largely on improving boron targeting to tumor cells. Seeking to maximize the potential of BNCT for the treatment for head and neck cancer, the aim of the present study was to perform boron biodistribution studies in the oral cancer model employing two different liposome formulations that were previously tested for a different pathology, i.e., in experimental mammary carcinoma in BALB/c mice: (1) MAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a hypertonic buffer, administered intravenously at 6 mg B per kg body weight, and (2) MAC-TAC: liposomes incorporating K[nido-7-CH(3)(CH(2))(15)-7,8-C(2)B(9)H(11)] in the bilayer membrane and encapsulating a concentrated aqueous solution of the hydrophilic species Na(3) [ae-B(20)H(17)NH(3)], administered intravenously at 18 mg B per kg body weight. Samples of tumor, precancerous and normal pouch tissue, spleen, liver, kidney, and blood were taken at different times post-administration and processed to measure boron content by inductively coupled plasma mass spectrometry. No ostensible clinical toxic effects were observed with the selected formulations. Both MAC and MAC-TAC delivered boron selectively to tumor tissue. Absolute tumor values for MAC-TAC peaked to 66.6 ± 16.1 ppm at 48 h and to 43.9 ± 17.6 ppm at 54 h with very favorable ratios of tumor boron relative to precancerous and normal tissue, making these protocols particularly worthy of radiobiological assessment. Boron concentration values obtained would result in therapeutic BNCT doses in tumor without exceeding radiotolerance in precancerous/normal tissue at the thermal neutron facility at RA-3.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, San Martin, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Monti Hughes A, Pozzi ECC, Heber EM, Thorp S, Miller M, Itoiz ME, Aromando RF, Molinari AJ, Garabalino MA, Nigg DW, Trivillin VA, Schwint AE. Boron Neutron Capture Therapy (BNCT) in an oral precancer model: therapeutic benefits and potential toxicity of a double application of BNCT with a six-week interval. Oral Oncol 2011; 47:1017-22. [PMID: 21840244 DOI: 10.1016/j.oraloncology.2011.07.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Revised: 07/15/2011] [Accepted: 07/19/2011] [Indexed: 11/19/2022]
Abstract
Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6 week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6 weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10+BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reactor and followed the animals for 8 months. The control group was cancerized and sham-irradiated. BPA-BNCT, (GB-10+BPA)-BNCT and beam-only induced a reduction in tumor development from premalignant tissue that persisted until 8, 3, and 2 months respectively. An early maximum inhibition of 100% was observed for all 3 protocols. No normal tissue radiotoxicity was detected. Reversible mucositis was observed in premalignant tissue, peaking at 1 week and resolving by the third week after each irradiation. Mucositis after the second application was not exacerbated by the first application. DNA synthesis was significantly reduced in premalignant tissue 8 months post-BNCT. A double application of BPA-BNCT and (GB-10+BPA)-BNCT, 6 weeks apart, could be used therapeutically at no additional cost in terms of radiotoxicity in normal and dose-limiting tissues.
Collapse
|
12
|
Molinari AJ, Pozzi ECC, Hughes AM, Heber EM, Garabalino MA, Thorp SI, Miller M, Itoiz ME, Aromando RF, Nigg DW, Quintana J, Santa Cruz GA, Trivillin VA, Schwint AE. “Sequential” Boron Neutron Capture Therapy (BNCT): A Novel Approach to BNCT for the Treatment of Oral Cancer in the Hamster Cheek Pouch Model. Radiat Res 2011; 175:463-72. [DOI: 10.1667/rr2148.1] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Garabalino MA, Monti Hughes A, Molinari AJ, Heber EM, Pozzi ECC, Cardoso JE, Colombo LL, Nievas S, Nigg DW, Aromando RF, Itoiz ME, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) for the treatment of liver metastases: biodistribution studies of boron compounds in an experimental model. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2011; 50:199-207. [PMID: 21132507 DOI: 10.1007/s00411-010-0345-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2010] [Accepted: 11/13/2010] [Indexed: 05/17/2023]
Abstract
We previously demonstrated the therapeutic efficacy of different boron neutron capture therapy (BNCT) protocols in an experimental model of oral cancer. BNCT is based on the selective accumulation of (10)B carriers in a tumor followed by neutron irradiation. Within the context of exploring the potential therapeutic efficacy of BNCT for the treatment of liver metastases, the aim of the present study was to perform boron biodistribution studies in an experimental model of liver metastases in rats. Different boron compounds and administration conditions were assayed to determine which administration protocols would potentially be therapeutically useful in in vivo BNCT studies at the RA-3 nuclear reactor. A total of 70 BDIX rats were inoculated in the liver with syngeneic colon cancer cells DHD/K12/TRb to induce the development of subcapsular tumor nodules. Fourteen days post-inoculation, the animals were used for biodistribution studies. We evaluated a total of 11 administration protocols for the boron compounds boronophenylalanine (BPA) and GB-10 (Na(2)(10)B(10)H(10)), alone or combined at different dose levels and employing different administration routes. Tumor, normal tissue, and blood samples were processed for boron measurement by atomic emission spectroscopy. Six protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue. Boron concentration values in tumor and normal tissues in the liver metastases model show it would be feasible to reach therapeutic BNCT doses in tumor without exceeding radiotolerance in normal tissue at the thermal neutron facility at RA-3.
Collapse
Affiliation(s)
- Marcela A Garabalino
- Department of Radiobiology, National Atomic Energy Commission, Avenida General Paz 1499, B1650KNA, San Martin, Province Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Voyant C, Roustit R, Tatje J, Biffi K, Leschi D, Briançon J, Marcovici CL. Therapeutic potential of atmospheric neutrons. Rep Pract Oncol Radiother 2011; 16:21-31. [PMID: 24669300 PMCID: PMC3920293 DOI: 10.1016/j.rpor.2010.11.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Revised: 10/05/2010] [Accepted: 11/03/2010] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND Glioblastoma multiform (GBM) is the most common and most aggressive type of primary brain tumour in humans. It has a very poor prognosis despite multi-modality treatments consisting of open craniotomy with surgical resection, followed by chemotherapy and/or radiotherapy. Recently, a new treatment has been proposed - Boron Neutron Capture Therapy (BNCT) - which exploits the interaction between Boron-10 atoms (introduced by vector molecules) and low energy neutrons produced by giant accelerators or nuclear reactors. METHODS The objective of the present study is to compute the deposited dose using a natural source of neutrons (atmospheric neutrons). For this purpose, Monte Carlo computer simulations were carried out to estimate the dosimetric effects of a natural source of neutrons in the matter, to establish if atmospheric neutrons interact with vector molecules containing Boron-10. RESULTS The doses produced (an average of 1 μGy in a 1 g tumour) are not sufficient for therapeutic treatment of in situ tumours. However, the non-localised yet specific dosimetric properties of 10B vector molecules could prove interesting for the treatment of micro-metastases or as (neo)adjuvant treatment. On a cellular scale, the deposited dose is approximately 0.5 Gy/neutron impact. CONCLUSION It has been shown that BNCT may be used with a natural source of neutrons, and may potentially be useful for the treatment of micro-metastases. The atmospheric neutron flux is much lower than that utilized during standard NBCT. However the purpose of the proposed study is not to replace the ordinary NBCT but to test if naturally occurring atmospheric neutrons, considered to be an ionizing pollution at the Earth's surface, can be used in the treatment of a disease such as cancer. To finalize this study, it is necessary to quantify the biological effects of the physically deposited dose, taking into account the characteristics of the incident particles (alpha particle and Lithium atom) and radio-induced effects (by-stander and low dose effect). One of the aims of the presented paper is to propose to experimental teams (which would be interested in studying the phenomena) a simple way to calculate the dose deposition (allometric fit of free path, transmission factor of brain).
Collapse
Affiliation(s)
- Cyril Voyant
- University of Corsica, CNRS UMR SPE 6134, Campus Grimaldi, 20250 Corte, France
- Castelluccio Hospital, Radiotherapy Unit, BP 85, 20177 Ajaccio, France
| | - Rudy Roustit
- Castelluccio Hospital, Radiotherapy Unit, BP 85, 20177 Ajaccio, France
| | - Jennifer Tatje
- Castelluccio Hospital, Radiotherapy Unit, BP 85, 20177 Ajaccio, France
| | - Katia Biffi
- Castelluccio Hospital, Radiotherapy Unit, BP 85, 20177 Ajaccio, France
| | - Delphine Leschi
- Castelluccio Hospital, Radiotherapy Unit, BP 85, 20177 Ajaccio, France
| | - Jérome Briançon
- Castelluccio Hospital, Radiotherapy Unit, BP 85, 20177 Ajaccio, France
| | | |
Collapse
|
15
|
Aromando RF, Trivillin VA, Heber EM, Pozzi E, Schwint AE, Itoiz ME. Early effect of boron neutron capture therapy mediated by boronophenylalanine (BPA–BNCT) on mast cells in premalignant tissue and tumors of the hamster cheek pouch. Oral Oncol 2010; 46:355-9. [DOI: 10.1016/j.oraloncology.2010.02.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2010] [Revised: 02/11/2010] [Accepted: 02/12/2010] [Indexed: 10/19/2022]
|
16
|
Wittig A, Huiskamp R, Moss RL, Bet P, Kriegeskotte C, Scherag A, Hilken G, Sauerwein WAG. Biodistribution of (10)B for Boron Neutron Capture Therapy (BNCT) in a mouse model after injection of sodium mercaptoundecahydro-closo-dodecaborate and l-para-boronophenylalanine. Radiat Res 2009; 172:493-9. [PMID: 19772470 DOI: 10.1667/rr1700.1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
In boron neutron capture therapy, the absorbed dose from the (10)B(n,alpha)(7)Li reaction depends on the (10)B concentration and (10)B distribution in the irradiated volume. Thus compounds used in BNCT should have tumor-specific uptake and low accumulation in normal tissues. This study compares in a mouse model the (10)B uptake in different organs as delivered by l-para-boronophenylalanine (BPA, 700 mg/kg body weight, i.p.) and/or sodium mercaptoundecahydro-closo-dodecaborate (BSH, 200 mg/kg body weight, i.p). After BSH injection, the (10)B concentration was high in kidneys (20 +/- 12 microg/g) and liver (20 +/- 12 microg/g) but was low in brain (1.0 +/- 0.8 microg/g) and muscle (1.9 +/- 1.2 microg/g). After BPA injection, the (10)B concentration was high in kidneys (38 +/- 25 microg/g) and spleen (17 +/- 8 microg/g) but low in brain (5 +/- 3 microg/g). After combined BPA and BSH injection, the effect on the absolute (10)B concentration was additive in all organs. The ratio of the (10)B concentrations in tissues and blood differed significantly for the two compounds depending on the compound combination, which implies a different uptake profile for normal organs.
Collapse
Affiliation(s)
- Andrea Wittig
- Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, University Hospital Essen, Essen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Cardoso JE, Trivillin VA, Heber EM, Nigg DW, Calzetta O, Blaumann H, Longhino J, Itoiz ME, Bumaschny E, Pozzi E, Schwint AE. Effect of Boron Neutron Capture Therapy (BNCT) on normal liver regeneration: Towards a novel therapy for liver metastases. Int J Radiat Biol 2009; 83:699-706. [PMID: 17729164 DOI: 10.1080/09553000701570212] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
PURPOSE The effect of Boron Neutron Capture Therapy (BNCT) on normal liver regeneration was examined in the Wistar rat. The model used is clinically relevant to a novel technique proposed for the treatment of multifocal non-resectable liver metastases in man. The success of the technique also requires that BNCT should not significantly impair regeneration of normal hepatocytes. MATERIALS AND METHODS The effect of therapeutic doses of boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) and (GB-10 + BPA) and of BNCT mediated by these boron delivery agents on normal liver regeneration and liver function in the Wistar rat was examined using partial hepatectomy as the regenerative stimulus. The end-points evaluated were body weight, liver weight/body weight ratio, DNA synthesis in terms of 5-bromo-2'-deoxyuridine incorporation, hemogram, kidney function in terms of blood urea nitrogen and creatinine levels, liver function in terms of serum albumin, total and direct bilirubin and liver enzymes (alanine transaminase and aspartate transaminase) and liver histology/architecture. RESULTS BNCT mediated by BPA, GB-10 or (GB-10 + BPA) did not cause alterations in the outcome of normal liver regeneration, regenerated liver function/proliferation or histology/architecture. CONCLUSION The BNCT protocols, at the physical doses selected, did not impair the capacity of normal liver hepatocytes to regenerate.
Collapse
Affiliation(s)
- Jorge E Cardoso
- Instituto de Oncología Angel H. Roffo, University of Buenos Aires
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Wittig A, Collette L, Moss R, Sauerwein W. Early clinical trial concept for boron neutron capture therapy: A critical assessment of the EORTC trial 11001. Appl Radiat Isot 2009; 67:S59-62. [DOI: 10.1016/j.apradiso.2009.03.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Monti Hughes A, Heber EM, Pozzi E, Nigg DW, Calzetta O, Blaumann H, Longhino J, Nievas SI, Aromando RF, Itoiz ME, Trivillin VA, Schwint AE. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT. Appl Radiat Isot 2009; 67:S313-7. [PMID: 19376711 DOI: 10.1016/j.apradiso.2009.03.070] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
We previously demonstrated the efficacy of boron neutron capture therapy (BNCT) mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) and (GB-10+BPA) to control tumors, with no normal tissue radiotoxicity, in the hamster cheek pouch oral cancer model. Herein we developed a novel experimental model of field-cancerization and precancerous lesions (globally termed herein precancerous tissue) in the hamster cheek pouch to explore the long-term potential inhibitory effect of the same BNCT protocols on the development of second primary tumors from precancerous tissue. Clinically, second primary tumor recurrences occur in field-cancerized tissue, causing therapeutic failure. We performed boron biodistribution studies followed by in vivo BNCT studies, with 8 months follow-up. All 3 BNCT protocols induced a statistically significant reduction in tumor development from precancerous tissue, reaching a maximum inhibition of 77-100%. The inhibitory effect of BPA-BNCT and (GB-10+BPA)-BNCT persisted at 51% at the end of follow-up (8 months), whereas for GB-10-BNCT it faded after 2 months. Likewise, beam-only elicited a significant but transient reduction in tumor development. No normal tissue radiotoxicity was observed. At 8 months post-treatment with BPA-BNCT or (GB-10+BPA)-BNCT, the precancerous pouches that did not develop tumors had regained the macroscopic and histological appearance of normal (non-cancerized) pouches. A potential new clinical application of BNCT would lie in its capacity to inhibit local regional recurrences.
Collapse
Affiliation(s)
- A Monti Hughes
- Department of Radiobiology, National Atomic Energy Commission (CNEA), Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: application to the treatment of experimental oral cancer. Appl Radiat Isot 2009; 67:S309-12. [PMID: 19380233 DOI: 10.1016/j.apradiso.2009.03.069] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1 x 10(9) n cm(-2)s(-1) and the fast neutron flux was 2.5 x 10(6) n cm(-2)s(-1), indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in (6)Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.
Collapse
|
21
|
Aromando RF, Heber EM, Trivillin VA, Nigg DW, Schwint AE, Itoiz ME. Insight into the mechanisms underlying tumor response to boron neutron capture therapy in the hamster cheek pouch oral cancer model. J Oral Pathol Med 2009; 38:448-54. [PMID: 19141057 DOI: 10.1111/j.1600-0714.2008.00720.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The therapeutic success of different boron neutron capture therapy (BNCT) protocols employing the hamster cheek pouch oral cancer model has been previously reported by our laboratory. The aim of this study was to explore potential mechanisms of BNCT-induced damage to tumor in terms of potential inhibition in DNA synthesis and induction of apoptosis in the tumors that underwent partial remission following application of the different BNCT protocols in this model. MATERIALS AND METHODS We evaluated DNA synthesis employing incorporation of 5-bromo-2'-deoxyuridine as an end-point. Apoptosis was evaluated by immunohistochemistry employing the deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling technique and Bax and Bcl-2 labeling. These studies were performed in tumors that underwent partial remission 1-30 days post-BNCT mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) or (BPA + GB-10). RESULTS BNCT exerted a marked inhibitory effect on DNA synthesis in tumors for all the protocols under study. The inhibitory effect of BPA-BNCT occurred as soon as 1 day post-treatment (P < 0.001). Conversely, the effect of GB-10-BNCT became apparent 7-14 days after therapy (P < 0.001) and was sustained until killed at 30 days post-treatment (P < 0.001). (GB-10 + BPA)-BNCT exerted a rapid and persistent effect, conceivably because of the combined effect of BNCT mediated by both boron compounds. The apoptosis studies did not show differences between the pre-treatment group and any of the BNCT groups. CONCLUSIONS One of the mechanisms involved in BNCT-induced tumor control in our model would be an inhibitory effect on DNA synthesis. Apoptosis does not seem to have a significant role in BNCT-induced tumor control in our model.
Collapse
Affiliation(s)
- Romina F Aromando
- Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires, Buenos Aires, Argentina.
| | | | | | | | | | | |
Collapse
|
22
|
Trivillin VA, Heber EM, Rao M, Cantarelli MA, Itoiz ME, Nigg DW, Calzetta O, Blaumann H, Longhino J, Schwint AE. Boron neutron capture therapy (BNCT) for the treatment of spontaneous nasal planum squamous cell carcinoma in felines. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2008; 47:147-155. [PMID: 17955256 DOI: 10.1007/s00411-007-0138-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2007] [Accepted: 10/04/2007] [Indexed: 05/25/2023]
Abstract
Recently, Boron neutron capture therapy (BNCT) was successfully applied to treat experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa, with no damage to normal tissue. It was also shown that treating spontaneous nasal planum SCC in terminal feline patients with low dose BNCT is safe and feasible. In an extension of this work, the present study aimed at evaluation of the response of tumor and dose-limiting normal tissues to potentially therapeutic BNCT doses. Biodistribution studies with (10)B-boronophenylalanine (BPA enriched in (10)B) as a (10)B carrier were performed on three felines that showed advanced nasal planum SCC without any standard therapeutic option. Following the biodistribution studies, BNCT mediated by (10)BPA was done using the thermalized epithermal neutron beam at the RA-6 Nuclear Reactor. Follow-up included clinical evaluation, assessment of macroscopic tumor and normal tissue response and biopsies for histopathological analysis. The treated animals did not show any apparent radiation-induced toxicity. All three animals exhibited partial tumor control and an improvement in clinical condition. Enhanced therapeutic efficacy was associated with a high (10)B content of the tumor and a small tumor size. BNCT is therefore believed to be potentially effective in the treatment of spontaneous SCC. However, improvement in targeting (10)B into all tumor cells and delivering a sufficient dose at a greater depth are still required for the treatment of deep-seated, large tumors. Future studies are needed to evaluate the potential efficacy of the dual mode cellular (e.g. BPA-BNCT) and vascular (e.g. GB-10-BNCT) targeting protocol in a preclinical scenario, employing combinations of (10)B compounds with different properties and complementary uptake mechanisms.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, B1650KNA, San Martin, Province Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Heber EM, Aromando RF, Trivillin VA, Itoiz ME, Nigg DW, Kreimann EL, Schwint AE. Therapeutic effect of boron neutron capture therapy (BNCT) on field cancerized tissue: Inhibition of DNA synthesis and lag in the development of second primary tumors in precancerous tissue around treated tumors in DMBA-induced carcinogenesis in the hamster cheek pouch oral cancer model. Arch Oral Biol 2007; 52:273-9. [PMID: 17137553 DOI: 10.1016/j.archoralbio.2006.10.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2006] [Revised: 09/18/2006] [Accepted: 10/07/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVE We previously reported the therapeutic success of different BNCT protocols in the treatment of oral cancer, employing the hamster cheek pouch model. The aim of the present study was to evaluate the effect of these BNCT protocols on DNA synthesis in precancerous and normal tissue in this model and assess the potential lag in the development of second primary tumors in precancerous tissue. The data are relevant to potential control of field cancerized tissue and tolerance of normal tissue. MATERIALS AND METHODS We evaluated DNA synthesis in precancerous and normal pouch tissue 1-30 days post-BNCT mediated by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) or (BPA+GB-10) employing incorporation of 5-bromo-2'-deoxyuridine as an end-point. The BNCT-induced potential lag in the development of second primary tumors from precancerous tissue was monitored. RESULTS A drastic, statistically significant reduction in DNA synthesis occurred in precancerous tissue as early as 1 day post-BNCT and was sustained at virtually all time-points until 30 days post-BNCT for all the protocols. The histological categories evaluated individually within precancerous tissue (dysplasia, hyperplasia and NUMF [no unusual microscopic features]) responded similarly. DNA synthesis in normal tissue treated with BNCT oscillated around the very low pre-treatment values. A BNCT-induced lag in the development of second primary tumors was observed. CONCLUSIONS BNCT induced a drastic fall in DNA synthesis in precancerous tissue that would be associated to the observed lag in the development of second primary tumors. The minimum variations in DNA synthesis in BNCT-treated normal tissue would correlate with the absence of normal tissue radiotoxicity. The present data would support the control of field-cancerized areas by BNCT.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, Avenida General Paz 1499, B1650KNA San Martín, Prov Buenos Aires, Argentina
| | | | | | | | | | | | | |
Collapse
|
24
|
Prikaznov AV, Bragin VI, Davydova MN, Sivaev IB, Bregadze VI. Synthesis of Alkoxy Derivatives of Decahydro-closo-decaborate Anion. ACTA ACUST UNITED AC 2007. [DOI: 10.1135/cccc20071689] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Synthesis of alkoxy derivatives of closo-decaborate anion [1- and 2-B10H9OR]2- by reaction of the hydroxy derivatives with corresponding alkyl bromides was described. A new method of synthesis of 2-hydroxy derivative of closo-decaborate anion [2-B10H9OH]2- was proposed.
Collapse
|
25
|
Trivillin VA, Heber EM, Nigg DW, Itoiz ME, Calzetta O, Blaumann H, Longhino J, Schwint AE. Therapeutic Success of Boron Neutron Capture Therapy (BNCT) Mediated by a Chemically Non-selective Boron Agent in an Experimental Model of Oral Cancer: A New Paradigm in BNCT Radiobiology. Radiat Res 2006; 166:387-96. [PMID: 16881740 DOI: 10.1667/rr3592.1] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The hypothesis of boron neutron capture therapy (BNCT) research has been that the short-range, high-linear energy transfer radiation produced by the capture of thermal neutrons by (10)B will potentially control tumor and spare normal tissue only if the boron compound selectively targets tumor tissue within the treatment volume. In a previous in vivo study of low-dose BNCT mediated by GB-10 (Na(2)(10)B(10)H(10)) alone or combined with boronophenylalanine (BPA) in the hamster cheek pouch oral cancer model that was primarily designed to evaluate safety and feasibility, we showed therapeutic effects but no associated normal tissue radiotoxicity. In the present study, we evaluated the response of tumor, precancerous and normal tissue to high-dose BNCT mediated by GB-10 alone or combined with BPA. Despite the fact that GB-10 does not target hamster cheek pouch tumors selectively, GB-10-BNCT induced a 70% overall tumor response with no damage to normal tissue. (GB-10+BPA)-BNCT induced a 93% overall tumor response with no normal tissue radiotoxicity. Light microscope analysis showed that GB-10-BNCT selectively damages tumor blood vessels, sparing precancerous and normal tissue vessels. In this case, selective tumor lethality would thus result from selective blood vessel damage rather than from selective uptake of the boron compound.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission,San Martín, Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Heber EM, Trivillin VA, Nigg DW, Itoiz ME, Gonzalez BN, Rebagliati RJ, Batistoni D, Kreimann EL, Schwint AE. Homogeneous boron targeting of heterogeneous tumors for boron neutron capture therapy (BNCT): chemical analyses in the hamster cheek pouch oral cancer model. Arch Oral Biol 2006; 51:922-9. [PMID: 16696934 DOI: 10.1016/j.archoralbio.2006.03.015] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2005] [Revised: 03/14/2006] [Accepted: 03/27/2006] [Indexed: 11/27/2022]
Abstract
OBJECTIVE BNCT is a tumour cell targeted radiation therapy. Uniform targeting of heterogeneous tumours with therapeutically effective boron carriers would contribute to a therapeutic effect on all tumour cell populations and avoid radioresistant fractions. This remains an unresolved challenge. The aim of the present study was to evaluate the degree of variation in boron content delivered by boronophenylalanine (BPA), GB-10 (Na(2)(10)B(10)H(10)) and the combined administration of (BPA+GB-10) in different portions of tumour, precancerous tissue around tumour and normal pouch tissue in the hamster cheek pouch oral cancer model. MATERIALS AND METHODS Samples of different areas of tumour, precancerous tissue and normal pouch tissue were taken from tumour-bearing hamsters, 3h post-administration of i.p. BPA (15.5mg B/kg b.w.), or i.v. GB-10 (50mg B/kg b.w.), or 3h and 1.5h post-administration respectively of i.v. GB-10 (34.5mg B/b.w.) and sequential i.p. injections of BPA (total dose 31mg B/kg b.w.) given jointly. Boron content was evaluated by inductively coupled plasma optical emission spectroscopy (ICP-OES). The degree of homogeneity in boron targeting was assessed in terms of the coefficient of variation (V: [S.D./mean]x100) of boron values. Statistical analysis of the results was performed by one-way ANOVA and the least significant difference test. RESULTS GB-10 and GB-10 plus BPA achieved respectively a statistically significant 1.8- and 3.3-fold increase in targeting homogeneity over BPA. CONCLUSIONS The combined boron compound administration protocol contributes to homogeneous targeting of heterogeneous tumours and would be expected to increase therapeutic efficacy of BNCT.
Collapse
Affiliation(s)
- Elisa M Heber
- Department of Radiobiology, National Atomic Energy Commission, Av. General Paz 1499, B1650KNA San Martin, Prov. Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Rao M, Trivillin VA, Heber EM, Cantarelli MDLA, Itoiz ME, Nigg DW, Rebagliati RJ, Batistoni D, Schwint AE. BNCT of 3 cases of spontaneous head and neck cancer in feline patients. Appl Radiat Isot 2005; 61:947-52. [PMID: 15308173 DOI: 10.1016/j.apradiso.2004.05.016] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Having demonstrated BPA-BNCT induced control of experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa with no damage to normal tissue we explored the feasibility and safety of treating spontaneous head and neck tumors, with particular focus on SCC, of terminal feline patients with low dose BPA-BNCT employing the thermal beam of the RA-1 Reactor within a preclinical context. The biodistribution studies showed that, in all three cases evaluated, BPA delivered absolute boron values to tumor in the range that proved therapeutically useful in the experimental model of SCC. BPA-BNCT studies showed no radiotoxic effects, partial tumor control in terms of impaired growth and partial necrosis, an improvement in clinical condition and prolonged survival beyond the terminal condition of the feline patients at the time of recruitment.
Collapse
Affiliation(s)
- Mónica Rao
- Veterinary Oncology Center, Avenida del Libertador 15013, (1642) Acassuso, Prov. Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Trivillin VA, Heber EM, Itoiz ME, Nigg D, Calzetta O, Blaumann H, Longhino J, Schwint AE. Radiobiology of BNCT mediated by GB-10 and GB-10+BPA in experimental oral cancer. Appl Radiat Isot 2004; 61:939-45. [PMID: 15308172 DOI: 10.1016/j.apradiso.2004.05.015] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We previously reported biodistribution and pharmacokinetic data for GB-10 (Na(2)(10)B(10)H(10)) and the combined administration of GB-10 and boronophenylalanine (BPA) as boron delivery agents for boron neutron capture therapy (BNCT) in the hamster cheek pouch oral cancer model. The aim of the present study was to assess, for the first time, the response of hamster cheek pouch tumors, precancerous tissue and normal tissue to BNCT mediated by GB-10 and BNCT mediated by GB-10 and BPA administered jointly using the thermalized epithermal beam of the RA-6 Reactor at the Bariloche Atomic Center. GB-10 exerted 75.5% tumor control (partial+complete remission) with no damage to precancerous tissue around tumor or to normal tissue. Thus, GB-10 proved to be a therapeutically efficient boron agent in this model despite the fact that it is not taken up selectively by oral tumor tissue. GB-10 exerted a selective effect on tumor blood vessels leading to significant tumor control with a sparing effect on normal tissue. BNCT mediated by the combined administration of GB-10 and BPA resulted in a reduction in the dose to normal tissue and would thus allow for significant escalation of dose to tumor without exceeding normal tissue tolerance.
Collapse
Affiliation(s)
- Verónica A Trivillin
- Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission, Avenida General Paz 1499, (1650) San Martín, Provincia de Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|